Is Galapagos N.V. (GLPG) a Buy, Sell, or Hold?
Galapagos N.V.
NASDAQ:GLPG
$27.98 USD
$0.47 (1.71%)
- Volume
- 2.38K
- Average Volume
- 153.2K
- Market Capitalization
- $1.84B
- P/E Ratio
- 3.30
- Dividend Yield
- 0.00%
- Price Target
- $33.00
- Year High
- $37.78
- Year Low
- $24.74
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $30.48
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Henry O. Gosebruch |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | GLPG |
| CUSIP | 36315X101 |
| CIK | 0001421876 |
| Web | https://www.glpg.com |
| Phone | 32 1 534 29 00 |
| Currency | USD |
| Employees | 452 |
| Country | BE |
Liquidity
| Debt-to-Equity Ratio | 0.00 |
| Payout Ratio | 0.00 |
| Current Ratio | 30.48 |
| Quick Ratio | 30.30 |
| Cash Ratio | 0.67 |
Sales & Book Value
| Annual Sales | $1.11B |
| Price / Sales | 1.54 |
| Cash Flow | -4.62 |
| Price / Cash Flow | -5.28 |
| Price / Book | 0.49 |
Price Target and Rating
| Average Stock Price Forecast | $33.00 |
| High Stock Price Forecast | $33.00 |
| Low Stock Price Forecast | $33.00 |
| Forecast Upside/Downside | -15.21% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 24 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $4.85 |
| Trailing P/E Ratio | 3.30 |
| PEG Ratio | -0.09 |
| P/E Growth | -0.09 |
| Net Income | $320.88M |
| Net Margin | 46.83% |
| Pretax Margin | 45.14% |
| Return on Equity | 16.28% |
| Return on Assets | 14.49% |
Financials Score
| AltmanZ Score | 9.79 |
| Piotroski Score | 4.00 |
| Working Capital | 2.96B |
| Total Assets | 3.37B |
| Ebit | 197.7M |
| Market Cap | 1.62B |
| Total Liabilities | 119.06M |
Poll Results
About Galapagos N.V. (NASDAQ:GLPG) Stock
Galapagos NV is a biotechnology company, which engages in the identification and development of small molecule and antibody therapies. Its clinical pipeline includes filgotinib, GLP3667, Toledo program, and idiopathic pulmonary fibrosis. The company was founded by Onno van de Stolpe, Rudi Pauwels, and Helmuth van Es on June 30, 1999 and is headquartered in Mechelen, Belgium. ...
Galapagos NV (GLPG) Q1 2026 Earnings Call Transcript
2026-05-07 11:21:21
Galapagos NV (GLPG) Q1 2026 Earnings Call Transcript
Galapagos Reports First Quarter 2026 Financial Results and Provides Business Update
2026-05-06 16:01:00
Galapagos' name change to Lakefront Biotherapeutics approved at the Company's EGM (Euronext & NASDAQ: LKFT) Collaboration Agreement with Gilead to advance potential First and Best-in-Class T Cell Engager expected to close in the Second Quarter of 2026 Following this transaction, including estimated associated R&D spend until first approval, the Company will continue to have a majority of its current cash remaining for additional strategic transactions and other capital allocation priorities Year-end 2026 cash and financial investments balance expected to be approximately €2B Management to host conference call on May 7, 2026, at 14:00 CET / 8:00 am ET Mechelen, Belgium ; May 6, 2026, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today reported its financial results for the first quarter of 2026 and provided a business update. “Having joined the company just one year ago, I'm thrilled with our progress. I am looking forward to consummating our partnership with Gilead and adding Ouro Medicines' talented team and its portfolio of programs to our Company, including the potential first and best in class T cell engager in autoimmune diseases, gamgertamig (OM336). We are excited that our Company is rebranding as Lakefront Biotherapeutics as this name reflects our Company's strategic evolution,” said Henry Gosebruch, Chief Executive Officer of Galapagos. Aaron Cox, Chief Financial Officer of Galapagos, added, “Following the anticipated use of cash to fund our collaboration with Gilead concerning its acquisition of Ouro Medicines, the Company will remain robustly capitalized and will have increased flexibility, including the ability to spend up to $500 million for business development independent of Gilead and not subject to our 2019 Option, License, and Collaboration Agreement with Gilead. This would also include the potential to use up to $150 million of that $500 million for share repurchases to the extent that we have available distributable reserves. In addition to the upfront consideration of $837.5 million, we anticipate additional 2026 Ouro-related cash expenditures to be in the range of €60-75 million, inclusive of R&D costs, one-time transaction costs and assuming a mid-year closing of the transaction.” First Quarter 2026 Business Update
2026-04-28 16:01:00
Mechelen, Belgium; April 28, 2026, 22:01 CET — Galapagos NV (Euronext & NASDAQ: GLPG) today announces that all resolutions proposed at the Company's Annual and Extraordinary Shareholders' Meetings (AGM and EGM) held on 28 April 2026 were approved.
Frequently Asked Questions
-
What is the current Galapagos N.V. (GLPG) stock price?
-
Galapagos N.V.(NASDAQ:GLPG) stock price is $27.98 in the last trading session. During the trading session, GLPG stock reached the peak price of $37.78 while $24.74 was the lowest point it dropped to. The percentage change in GLPG stock occurred in the recent session was 1.71% while the dollar amount for the price change in GLPG stock was $0.47.
-
GLPG's industry and sector of operation?
-
The NASDAQ listed GLPG is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of GLPG?
-
Henry Gosebruch | Chief Executive Officer & Executive Director
Annelies Missotten | Executive Officer
Ellen Van Der Aar | Head of Development
Ruiz Astigarraga | Head of Manufacturing Cell Therapy
Marieke Vermeersch | Head of Corporation Communication -
How many employees does GLPG have?
-
Number of GLPG employees currently stands at 452. GLPG operates from Generaal De Wittelaan L11 A3, Mechelen, None 2800, BE.
-
Link for GLPG official website?
-
Official Website of GLPG is: https://www.glpg.com
-
How do I contact GLPG?
-
GLPG could be contacted at phone #32 1 534 29 00 and can also be accessed through its website. GLPG operates from Generaal De Wittelaan L11 A3, Mechelen, None 2800, BE.
-
How many shares of GLPG are traded daily?
-
The average number of GLPG shares traded daily for last 3 months was 153.2K.
-
What is the market cap of GLPG currently?
-
The market value of GLPG currently stands at $1.84B with its latest stock price at $27.98